Clinical trials: Pyoderma Gangrenosum
Pyoderma Gangrenosum, Crohn's Disease
Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease
Subjects must be 18- 75 years old and have a history of both inflammatory bowels disease (Crohn's or ulcerative colitis) and pyoderma gangrenosum. This is a 6 month open label study of an intravenous (IV) medication.
- Conditions
- Pyoderma Gangrenosum, Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Disease
- Trial name
- NCT00791557
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University Hospitals Cleveland Medical Center
Pyoderma Gangrenosum
An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum
An Open-Label, Proof-Of-Concept, Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum
- Trial name
- NCT03137160
- Testing
- Ixekizumab
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Pyoderma, Pyoderma Gangrenosum
Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma
Phase 0/1 local application of the monoclonal antibody (Mab) sB24M in patients with purulent pyoderma (chronic ulcerative pyoderma) by injection into the affected areas.
- Conditions
- Pyoderma, Pyoderma Gangrenosum, Pyoderma Vegetans, Pyoderma Gangrenosum Surrounding Surgical Stoma
- Trial name
- NCT04895566
- Testing
- Monoclonal antibody (Mab) sB24M
- Where
- 2 sites in Belarus, Latvia
- Volunteers
- 10 people
- Sponsor
- SWISS BIOPHARMA MED GmbH
Pyoderma Gangrenosum
Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum
The purpose of this study is to determine the safety and efficacy of Humira in the treatment of pyoderma gangrenosum.
- Trial name
- NCT00730717
- Testing
- Humira
- Where
- United States
- Sponsor
- Wright State University
Pyoderma Gangrenosum
Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum
The study will evaluate the safety and biologic activity of gevokizumab in subjects in the acute inflammatory phase of pyoderma gangrenosum.
- Trial name
- NCT01882504
- Testing
- gevokizumab
- Where
- 19 sites in United States
- Volunteers
- 8 people
- Sponsor
- XOMA (US) LLC
Pyoderma Gangrenosum
A Clinical Study Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Ulcerative Pyoderma Gangrenosum
This study was designed to assess the therapeutic efficacy and safety of SHR-1139 Injection in adult patients with ulcerative pyoderma gangrenosum.
- Trial name
- NCT07337564
- Testing
- SHR-1139 Injection
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shandong First Medical University
Diabetic Foot, Pressure Ulcer
A Real-World Registry of Chronic Wounds and Ulcers
WOUNDJOURNEY is a longitudinal, real-world, observational registry designed to capture the full clinical course and patient journey associated with chronic wounds and ulcers.
- Conditions
- Diabetic Foot, Pressure Ulcer, Surgical Wound Dehiscence, Vasculitis
- Trial name
- WOUNDJOURNEY (NCT02280733)
- Testing
- Usual care
- Where
- United States
- Volunteers
- 300,000 people
- Sponsor
- U.S. Wound Registry
Pyoderma Gangrenosum
An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum
The study will evaluate the efficacy and safety of gevokizumab in treating active ulcers of pyoderma gangrenosum (PG).
- Trial name
- NCT02315417
- Testing
- gevokizumab, gevokizumab open-label
- Where
- 12 sites in United States
- Volunteers
- 16 people
- Sponsor
- XOMA (US) LLC
Pyoderma Gangrenosum
A Study to Evaluate SHR-1139 Injection in Patients With Pyoderma Gangrenosum
This study aims to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of SHR-1139 Injection in patients with pyoderma gangrenosum.
- Trial name
- NCT07444684
- Testing
- SHR-1139 Injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Pyoderma Gangrenosum
Deucravacitinib in PG
The main goal of this study is to see if the study drug called "Deucravacitinib" is safe and effective in treating people with pyoderma gangrenosum (PG).
- Trial name
- NCT05821374
- Testing
- Deucravacitinib
- Where
- United States
- Sponsor
- Dartmouth-Hitchcock Medical Center
Pyoderma Gangrenosum
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
The purpose of this study is to find out whether a medicine called spesolimab helps people with pyoderma gangrenosum (PG). The main aim is to see whether spesolimab leads to closure of PG ulcers.
- Trial name
- NCT06624670
- Testing
- Spesolimab, Prednisone, Prednisolone
- Where
- 104 sites in United States, Argentina and 19 more
- Volunteers
- 90 people
- Sponsor
- LEO Pharma
Pyoderma Gangrenosum
Efficacy of Bimekizumab in Adults With Pyoderma Gangrenosum
The purpose of the study is to learn more about an experimental drug bimekizumab that may be helpful for Pyoderma Gangrenosum (PG). Bimekizumab will be referred to as the study drug throughout this form.
- Trial name
- BEAT-PG (NCT07767864)
- Testing
- Bimekizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Oregon Health and Science University
Pyoderma Gangrenosum
Spesolimab in Pyoderma Gangrenosum
The purpose of this research study is to assess the feasibility of using spesolimab in participants with moderate to severe pyoderma gangrenosum.
- Trial name
- NCT06092216
- Testing
- Spesolimab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Pyoderma Gangrenosum
A Novel Therapeutic Treatment of Pyoderma Gangrenosum
Pyoderma gangrenosum is a chronic debilitating ulcerative neutrophilic condition usually affecting the skin. The pathogenesis of pyoderma gangrenosum is poorly understood.
- Trial name
- NCT05120726
- Testing
- Dehydrated human amnion/chorion membrane
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans
Pyoderma Gangrenosum, Hidradenitis Suppurativa
JAK-STAT Signaling Pathway in Pyoderma Gangrenosum
The investigators hypothese that Janus kinase/signal transduction and activator of transcription (JAK/STAT) signaling pathway play a key role in pathophysiology of pyoderma gangrenosum (PG).
- Conditions
- Pyoderma Gangrenosum, Hidradenitis Suppurativa, Psoriasis
- Trial name
- NCT04792957
- Testing
- immunohistochemical methods
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Dokuz Eylul University
Pyoderma Gangrenosum
Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum
The purpose of this study is to explore the efficacy and safety of anti-Interleukin-(IL)17 therapy (secukinumab, administered weekly for 4 weeks followed by four-weekly administration until week 16) for the treatment of pyoderma…
- Trial name
- NCT02733094
- Testing
- Secukinumab
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- Technical University of Munich
Pyoderma Gangrenosum
Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum
A randomized, double-blind, placebo-controlled, multicenter, adaptive phase III trial to investigate efficacy and safety of vilobelimab in the treatment of ulcerative pyoderma gangrenosum
- Trial name
- NCT05964413
- Testing
- vilobelimab
- Where
- 50 sites in United States, Australia and 8 more
- Volunteers
- 54 people
- Sponsor
- InflaRx GmbH
Pyoderma Gangrenosum, Skin Diseases
Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)
An Open-Label, Proof-Of-Concept, Study of Baricitinib for the Treatment of Pyoderma Gangrenosum
- Conditions
- Pyoderma Gangrenosum, Skin Diseases, Wound Heal, Pyoderma
- Trial name
- NCT04901325
- Testing
- Baricitinib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Oregon Health and Science University
Pyoderma Gangrenosum
A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan
This study is designed to investigate the efficacy, safety and pharmacokinetics of adalimumab in subjects in Japan with active ulcer(s) due to Pyoderma Gangrenosum (PG).
- Trial name
- NCT03311464
- Testing
- adalimumab
- Where
- 20 sites in Japan
- Volunteers
- 22 people
- Sponsor
- AbbVie
Pyoderma Gangrenosum, Skin Diseases
Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
A single-arm open-label study assessing short-term (week 6, 16) and long-term (week 32) efficacy of guselkumab in adult participants with pyoderma gangrenosum (PG)
- Conditions
- Pyoderma Gangrenosum, Skin Diseases, Wound Heal, Pyoderma
- Trial name
- GEORGE (NCT06563323)
- Testing
- Guselkumab
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Oregon Health and Science University